Vezyx 5mg Davipharm treatments for allergic rhinitis, urticaria (2 blisters x 14 tablets)

After taking a single dose, levocetirizin is attached to 90% of the receptor after 4 hours and 57% of the receptor after 24 hours.

The mechanism of action of levocetirizin is similar to cetirizin.

In In vitro studies, levocetirizin inhibits the Eotaxin - Austura touch substance moves through skin and lung cells.

levocetirizin inhibits the early stage of allergic reactions through histamine intermediaries and also reduces the migration of certain inflammatory cells and the release of intermediates related to late allergic response.

Hematology/pharmacokinetic relevance:

levocetirizin 5 mg for urticaria and rash inhibitors due to histamine like Cetirizin 10 mg. Electrolyte shows that levocetirizin does not affect the QT.

pharmacokinetics

levocetirizin represents linear pharmacokinetics regardless of the dose and time with the difference between small objects. Pharmacokinetics when using levocetirizin or cetirizin are the same. There is no reversal in the process of absorption and elimination.

absorption

levocetirizin is quickly and strong after drinking. The peak concentration in plasma is 0.9 hours after drinking. Stable state achieved after 2 days. The peak concentration is usually 270 ng/ml and 308 ng/ml respectively after the single dose and the dose repeats 5 mg x 1 time/day. The level of absorption does not depend on the dose and is not affected by food but the peak concentration is reduced and slow.

Distribution

There is no information distributed in human tissue as well as levocetirizin through the bloody barrier. In mice and dogs, the highest tissue concentration found in the kidneys and liver, the lowest in the components of the central nervous system.

levocetirizin binds 90% to plasma proteins, limited distribution because the distribution volume is 0.4 l/kg.

Metabolism

The amount of levocetirizin metabolized in humans is lower than 14% of the dose and so the difference due to polymorphic genotype or used with enzyme inhibitors is negligible. The metabolic paths include aromatic oxidation, N-and O-DEALKYL chemical and taurin.

Dealyl pathway is mainly through CYP3A4 intermediaries while aromatic oxidation has the participation of many types of CYP and/ or CYP unknown. Levocetirizin does not affect the activity of CYP 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 at a much higher concentration than the peak concentration after taking the dose of 5 mg.

Due to poor metabolism and no metabolic inhibition, levocetirizin is less interactive with other substances, or vice versa.

Elimination

Selling time for adults is 7.9 ± 1.9 hours. The apparent body clearance is 0.63 ml/min/kg. Levocetirizin and metabolites are excreted mainly in urine, accounting for an average of 85.4% of the dose. The excretion through the stool accounts for an average of 12.9% of the dose. Levocetirizin is eliminated by glomerular filtration and active excretion in the renal tubules.

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Be cautious when using

should avoid using levocetirizin with alcohol or other central nervous system inhibitors because it can cause excessive decrease in and inhibit the central nervous system.

There has been an urinary retention reporting when using levocetirizin, so be careful when used in patients with risk factors for urinary retention (such as spinal cord lesions, prostate hyperplasia) because levocetirizin may increase the risk of urinary retention. Stop levocetirizin if the patient has urinary retention.

Do not overdose.

It is not recommended to use levocetirizin in children under 6 years old because of the form of dosage that does not match the dose.

Caution recommendations in epilepsy patients and patients are at risk of convulsions.

The drug contains lactose, a rare genetic disease, galactose intolerance, lactase deficiency or glucose-galactose absorption disorders should not use this drug.

Drugs that contain polysorbat 80 can cause allergies and castor oils that can cause nausea, vomiting, abdominal pain, diarrhea.

The ability to drive and operate machinery

In clinical trials, there is a drowsiness, fatigue and weakness when using levocetirizin. Remind patients to be cautious when participating in dangerous jobs that need mental concentration and coordination such as operating machinery or driving after taking Levocetirizin.

Pregnancy

The safety of levocetirizin for pregnant women has not been established. Very few clinical data on drug use in pregnant women. Animal research does not see drugs that affect pregnancy, embryo/fetal development, birth or development of children after birth.

Breastfeeding period

Cetirizin has been reported in breast milk. Because levocetirizin is also expected to produce breast milk, it is not recommended to use levocetirizin while breastfeeding.

Medicinal interaction

In vitro information shows levocetirizin does not cause pharmacokinetic interaction through inhibition or enzyme induction in the liver. No drug interaction studies - any in vivo drugs have been done with levocetirizin. Drug interaction research is done with Cetirizin Racemic.

antipyretic drugs, azithromycin, cimetidin, erythromycin, ketoconazole, theophylin and pseudoephedrin

Research on pharmacological interaction with Cetirizin Racemic shows that cetirizin does not interact with antipyretic drugs, azithromycin, cimetidine, erythromycin, ketoconazole and pseudephedrin. There is a slight decrease in cetirizin clearance (16%) when used with theophylin 400 mg. The higher theophylin dose may have more effects.

ritonavir

Ritonavir increases the plasma AUC of Cetirizin about 42%accompanied by an increase in the selling time (53%) and reducing clearance (29%). Ritonavir's excretion is not changed when used with cetirizin.

Food

Levocetirizin absorption level does not decrease when used with food, although the absorption speed decreases.